The expanding therapeutic and recreational use of psychedelics demands rigorous safety assessment beyond controlled clinical environments, where promising results may not reflect real-world risks. This analysis represents the first comprehensive examination of adverse events from actual psychedelic use across diverse populations worldwide.
Researchers analyzed WHO's global pharmacovigilance database, examining 2,056 adverse event reports for MDMA, LSD, psilocybin, DMT, and mescaline. MDMA generated the most reports (1,573), followed by LSD (394), with classical psychedelics showing lower reporting frequencies. Psychiatric complications dominated across all substances, particularly substance abuse and dependence patterns. Overdose events remained relatively uncommon at 1.1-1.7% of total reports, while pregnancy-related complications were rare. Notably, both LSD and MDMA showed dramatically elevated risks for substance use disorders compared to acetaminophen controls—LSD carried 71-fold higher odds, MDMA 130-fold higher odds.
These findings challenge the narrative that psychedelics carry minimal abuse potential, revealing significant gaps between clinical trial safety profiles and real-world outcomes. The psychiatric adverse events likely reflect both the substances' powerful psychological effects and potential for problematic use patterns outside therapeutic supervision. However, voluntary reporting systems inherently capture negative outcomes disproportionately, potentially skewing risk perceptions. The analysis cannot distinguish between therapeutic, supervised recreational, or unsupervised use contexts, limiting direct applicability to emerging therapeutic protocols. This data suggests that while psychedelics show therapeutic promise, their deployment requires sophisticated harm reduction frameworks and careful consideration of abuse liability—particularly as access expands beyond clinical settings into broader populations with varying mental health baselines and support systems.